SPmAb6™-Vaxil’s Antibody Platform

Anti-MUC1 antibodies in clinical development are directed against epitopes in MUC1’s extracellular domain which appears on tumor cells but also on patient’s blood thereby having reduced specificity and therapeutic potential. On the contrary, Vaxil’s SPmAb2.1 and SPmAb-6 anti-MUC1 signal peptide antibodies are targeting only MUC1-expressing tumor cells. An article, (link attached), discussing Vaxil's discovery and development of the anti-MUC1 signal peptide antibodies including their potential therapeutic role, was published in the Scientific Journal, PLos one.
​The company is ​also using the isolated antibodies SPmAb-2.1 and SPmAb-6 as a “companion diagnostic” to identify and follow the 'best patients' to benefit from ImMucin’s therapy. Since anti-MUC1 SP antibodies SPmAb-2.1 and SPmAb-6 target cellular MUC1 on tumor cells but not soluble MUC1 in patients’ blood they are far more specific vs. anther MUC1 antibodies and have huge potential for both therapeutic and diagnostic applications. Vaxil believes that its antibody platform has significant potential and is working to explore potential partnerships or other avenues for value realization

VAXIL – Creating the ideal immunotherapy

Inducing a Broad

Response

Learn More

universally

Applicable

Learn More

Overcoming

Cancer Resistance

Learn More

Harnessing Potent

Immune Response

Learn More

Tumor

Specific

Learn More

Expression on

Cancer Stem Cells

Learn More

neo-antigen

acting

Learn More

First Ever SP-Specific

Antibody Platform

Learn More

Vaxil’s Lead Products and Orphan Drug Status

Vaxil believes its immunotherapy platform allows it to target high profile cancer antigens in a uniquely superior manner, all designed to possess the novel advantages described above. Vaxil’s first test of its VaxHit™platform is ​its ImMucin™ ​lead immunotherapy product.